PT - JOURNAL ARTICLE AU - Jennifer L. Guthrie AU - Allison J. Chen AU - Dalton R. Budhram AU - Kirby Cronin AU - Adriana Peci AU - Paul Nelson AU - Gustavo V. Mallo AU - George Broukhanski AU - Michelle Murti AU - Anna Majury AU - Tony Mazzulli AU - Vanessa G. Allen AU - Samir N. Patel AU - Julianne V. Kus AU - Vanessa Tran AU - Jonathan B. Gubbay TI - Characteristics of SARS-CoV-2 Testing for Rapid Diagnosis of COVID-19 during the Initial Stages of a Global Pandemic AID - 10.1101/2020.12.23.20231589 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.23.20231589 4099 - http://medrxiv.org/content/early/2020/12/26/2020.12.23.20231589.short 4100 - http://medrxiv.org/content/early/2020/12/26/2020.12.23.20231589.full AB - Accurate SARS-CoV-2 diagnosis is essential to guide prevention and control of COVID-19. From January 11 – April 22, 2020, Public Health Ontario conducted SARS-CoV-2 testing of 86,942 specimens collected from 80,354 individuals, primarily using real-time reverse-transcription polymerase chain reaction (rRT-PCR) methods. We analyzed test results across specimen types and for individuals with multiple same-day and multi-day collected specimens. Nasopharyngeal compared to throat swabs had a higher positivity (8.8% vs. 4.8%) and an adjusted estimate 2.9 Ct lower (SE=0.5, p<0.001). Same-day specimens showed high concordance (98.8%), and the median Ct of multi-day specimens increased over time. Symptomatic cases had rRT-PCR results with an adjusted estimate 3.0 Ct (SE=0.5, p<0.001) lower than asymptomatic/pre-symptomatic cases. Overall test sensitivity was 84.6%, with a negative predictive value of 95.5%. Molecular testing is the mainstay of SARS-CoV-2 diagnosis and testing protocols will continue to be dynamic and iteratively modified as more is learned about this emerging pathogen.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was part of routine laboratory surveillance and thus it was supported through Public Health Ontario's operational funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Public Health Ontario Ethics Review Board has determined that this project did not require research ethics committee approval, as it describes analyses that were completed at Public Health Ontario Laboratory as part of routine clinical respiratory testing during the first wave of the COVID-19 pandemic in Ontario and are therefore considered public health practice.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPatient data cannot be shared publicly for ethical and legal reasons, as public availability would compromise patient privacy. Researchers who meet criteria for access to confidential data can contact the PHO Privacy Officer (privacy{at}oahpp.ca).